BALVERSA® - for Locally Advanced or Metastatic Urothelial Carcinoma
BALVERSA® (Erdafitinib) for Locally Advanced or Metastatic Urothelial Carcinoma with susceptible FGFR3 or FGFR2 genetic alterations
N/A
N/A
Monitor for hyperphosphatemia, hypercalcemia, ocular disorders and liver function abnormalities. The recommended starting dose of BALVERSA® is 8 mg orally once daily, with a dose increase to 9 mg once daily based on serum phosphate levels and tolerability at 14-21 days. Treatment should continue until disease progression or unacceptable toxicity occurs.
Drug Mode Given Standard Dose Days to Be Given Frequency Solution Volume Duration
BALVERSA® (Erdafitinib) PO 9 mg Daily N/A N/A N/A N/A